SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus

SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus

V937 is an oncolytic virus immunotherapy clinical drug candidate consisting of a proprietary formulation of Coxsackievirus A21 (CVA21). V937 specifically binds to and lyses cells with over-expressed ICAM-1 receptors in a range of tumor cell types and is currently in phase I and II clinical trials. I...

Full description

Bibliographic Details
Main Authors: James Z. Deng, Richard R. Rustandi, Andrew Swartz, Yvonne Shieh, Jack B. Baker, Josef Vlasak, Shiyi Wang, John W. Loughney
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Molecular Therapy: Oncolytics
Subjects:
Oncolytic Coxsackievirus A21 virus
empty and full capsid
size-exclusion chromatography
immunotherapy
capsid particle concentration
virus capsid empty/full ratio
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770521001790

Internet

http://www.sciencedirect.com/science/article/pii/S2372770521001790

Similar Items